Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type(CYNK001GBM02) | withdrawn | Phase 1 / Phase 2 | 0 | Celularity IncorporatedINDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT07553520 | Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | withdrawn | Phase 2 | 0 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05341947 | Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jeremy Rudnick, M.DOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04838782 | Role of Repeat Resection in Recurrent Glioblastoma | withdrawn | N/A | 0 | University of AlbertaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05927610 | Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma | withdrawn | N/A | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT05900908 | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy(PATHWAyS) | withdrawn | Phase 4 | 0 | GT Medical Technologies, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT05457959 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Tel Aviv Medical CenterOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression(GLIOASTRA) | withdrawn | Phase 1 | 0 | Philogen S.p.A.INDUSTRY | 0 | Apr 8, 2024 | clinicaltrials |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma(RiNG) | withdrawn | Phase 1 | 0 | University College, LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05054400 | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | withdrawn | Phase 1 | 0 | Y-mAbs TherapeuticsINDUSTRY | 0 | Jun 26, 2023 | clinicaltrials |
| NCT04741984 | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM(DEMAND) | withdrawn | Phase 1 | 0 | Michael GunnOTHER | 0 | May 15, 2023 | clinicaltrials |
| NCT05410301 | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | withdrawn | N/A | 0 | Varun Monga, MDOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03956706 | Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas | withdrawn | N/A | 0 | Northwell HealthOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | withdrawn | Early Phase 1 | 0 | Emory UniversityOTHER | 0 | Dec 2, 2022 | clinicaltrials |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | withdrawn | Phase 1 / Phase 2 | 0 | Oblato, Inc.INDUSTRY | 0 | Oct 7, 2022 | clinicaltrials |
| NCT04776980 | Multimodality MRI and Liquid Biopsy in GBM | withdrawn | Early Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | University of RochesterOTHER | 0 | Aug 22, 2022 | clinicaltrials |
| NCT04926168 | 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM) | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01331616 | Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab | withdrawn | Early Phase 1 | 0 | West Penn Allegheny Health SystemOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT03235934 | Glycemic Impact on Glioblastoma Outcomes | withdrawn | — | 0 | University Health Network, TorontoOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | withdrawn | Phase 2 | 0 | University of AarhusOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03980249 | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | withdrawn | Early Phase 1 | 0 | West Virginia UniversityOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | withdrawn | Phase 2 | 0 | John M. BuattiOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02919332 | Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma | withdrawn | — | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT00943462 | Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM | withdrawn | — | 0 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT02754362 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 12, 2019 | clinicaltrials |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | withdrawn | Early Phase 1 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | withdrawn | Phase 1 / Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)(PARADIGMA) | withdrawn | Phase 1 | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT00645385 | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.(Gliadel-MRS) | withdrawn | — | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jul 1, 2026source: clinicaltrials